Antimitochondrial antibodies in jaundice following drug administration.
D000328:Adult; D000368:Aged; D000636:Aminosalicylic Acids / Q000009:adverse effects; D000906:Antibodies / Q000032:analysis*; D002746:Chlorpromazine / Q000009:adverse effects*; D002747:Chlorpropamide / Q000009:adverse effects; D003937:Diagnosis, Differential; D005260:Female; D005455:Fluorescent Antibody Technique; D006221:Halothane / Q000009:adverse effects*; D006506:Hepatitis A / Q000175:diagnosis / Q000276:immunology; D006801:Humans; D007565:Jaundice / Q000139:chemically induced* / Q000175:diagnosis / Q000276:immunology; D008297:Male; D008750:Methyldopa / Q000009:adverse effects; D008875:Middle Aged; D008928:Mitochondria / Q000276:immunology*; D008930:Mitochondria, Liver / Q000276:immunology; D010546:Perphenazine / Q000009:adverse effects
D000636:Aminosalicylic Acids; D000906:Antibodies; D008750:Methyldopa; D010546:Perphenazine; D002746:Chlorpromazine; D006221:Halothane; D002747:Chlorpropamide